Publications by authors named "Lirui Liang"
Article Synopsis
- Radiation therapy is commonly used to treat hepatocellular carcinoma (HCC), but its effectiveness can be reduced by the over-expression of PD-L1, which promotes resistance to treatment.
- This study explores the potential of nifuroxazide to enhance radiotherapy's effectiveness by lowering PD-L1 levels, demonstrating that it increases tumor cell sensitivity to radiation while promoting cell death (apoptosis).
- Nifuroxazide not only inhibited tumor growth and improved survival rates in H22-bearing mice, but also helped decrease PD-L1 expression in tumor tissues, suggesting it may be a valuable adjunct to radiation therapy for HCC patients.
Melanoma, the most perilous form of skin cancer, is known for its inherent resistance to chemotherapy. Even with advances in tumor immunotherapy, the survival of patients with advanced or recurrent melanomas remains poor. Over time, melanoma tumor cells may produce excessive angiogenic factors, necessitating the use of combinations of angiogenesis inhibitors, including broad-spectrum options, to combat melanoma.
View Article and Find Full Text PDFArticle Synopsis
- Research highlights that PD-L1 upregulation in tumor cells suppresses T cell activity and that blocking PD-L1/PD-1 signaling is a key focus in immunotherapy.
- This study investigates the effects of the antidepressant maprotiline on melanoma in mice, revealing it inhibits tumor cell growth and enhances immune response.
- Findings indicate maprotiline decreases PD-L1 expression, boosts CD4+ and CD8+ T cell activity, and increases immune cell infiltration in tumors, suggesting its potential as a new therapeutic option for cancer treatment.
Article Synopsis
- * Radiation therapy (RT) is used for treating HCC that cannot be surgically removed, but a major problem is radioresistance, which can limit its effectiveness.
- * Researchers explored using attenuated Salmonella to deliver siRNA targeting PD-L1, finding that this combination with RT improved tumor response by lowering PD-L1 expression and enhancing immune activity, suggesting a new approach for treating radioresistant HCC.
Hepatocellular carcinoma (HCC) is a primary liver cancer representing serious harm to human health. The effective treatment of HCC is challenging. Lenvatinib is an inhibitor of polytyrosine kinase that exerts an effect against HCC by blocking the VEGF signaling pathway.
View Article and Find Full Text PDF